Biogen Faces Italian Antitrust Probe Over Multiple Sclerosis Drug Competition
[출처/시간] MT Newswires - 3:47 AM ET, 05/27/2026 03:47 AM EDT, 05/27/2026 (MT Newswires) -- Biogen (BIIB) and its Biogen Italia unit are under investigation over alleged abuse of dominant market position in Italy, the Italian Competition Authority said Wednesday. The watchdog is examining whether the companies restricted rival Sandoz from providing multiple sclerosis drugs by limiting access to an active ingredient. The probe centers on natalizum
[출처/시간] MT Newswires - 3:47 AM ET, 05/27/2026
03:47 AM EDT, 05/27/2026 (MT Newswires) -- Biogen (BIIB) and its Biogen Italia unit are under investigation over alleged abuse of dominant market position in Italy, the Italian Competition Authority said Wednesday.
The watchdog is examining whether the companies restricted rival Sandoz from providing multiple sclerosis drugs by limiting access to an active ingredient.
The probe centers on natalizumab, a treatment for rapidly evolving severe multiple sclerosis, according to the regulator.
Biogen did not immediately respond to MT Newswires' request for comment.
당신의 반응은 무엇인가요?
좋아요
0
싫어요
0
사랑
0
재미있는
0
화난
0
슬프다
0
와우
0
